Safe Co-Prescription of Melatonin and Hydroxychloroquine in Older Adults

Introduction to Safety Considerations

• The American College of Rheumatology recommends hydroxychloroquine dosing at ≤5 mg/kg actual body weight per day to minimize retinopathy risk, which is below 2% over 10 years 4
• The European League Against Rheumatism suggests that hydroxychloroquine is a weak inhibitor of CYP2D6 and P-glycoprotein (P-gp), requiring monitoring only with narrow-window drugs using these pathways 1, 2

Cardiac Monitoring and QT Prolongation

• The American Heart Association recommends that all medications with potential QT prolongation effects should be identified and ECG monitoring intensified when multiple agents are used 1, 2
• Risk factors for torsade de pointes include hypokalemia, bradycardia, and concomitant use of other QT-prolonging medications, according to the European Society of Cardiology 1, 2
• The National Institute for Health and Care Excellence advises obtaining baseline ECG to assess QT interval before initiating combination therapy with hydroxychloroquine and melatonin 1, 2, 3

Dosing and Renal Impairment

• The Kidney Disease: Improving Global Outcomes initiative recommends reducing hydroxychloroquine dose by 25% in patients with eGFR <30 ml/min per 1.73 m² 5, 6, 3
• The American Society of Nephrology suggests that renal impairment is the greatest modifiable risk factor for hydroxychloroquine toxicity 3

Ongoing Monitoring and Screening

• The Royal College of Ophthalmologists recommends ophthalmologic screening should begin after 5 years for low-risk patients, or after 1 year for high-risk patients (eGFR <60 ml/min per 1.73 m², concomitant tamoxifen, or dose >5 mg/kg/day) 4, 6, 3
• The European Society of Cardiology advises periodic ECG monitoring if multiple QT-prolonging agents are used 1, 2

Clinical Context for Autoimmune Disease Management

• The European League Against Rheumatism recommends hydroxychloroquine for all patients with lupus nephritis due to reduced flare risk, prevention of end-stage kidney disease, and mortality benefit 5, 6
• The American College of Rheumatology suggests that hydroxychloroquine should be continued at full dose when available for patients with stable rheumatic disease 7, 5